Class / Patent application number | Description | Number of patent applications / Date published |
435214000 | Thrombin | 8 |
20080274532 | Blood Coagulation Accelerator and Container for Blood Examination - The present invention provides a blood coagulation accelerator excellent under severe conditions at ordinary or higher temperatures and capable of exhibiting high blood coagulation performance stably over a long period of time, as well as a container for blood examination wherein the blood coagulation accelerator is accommodated. Disclosed is a blood coagulation accelerator comprising an enzyme capable of hydrolyzing in a peptide chain a bond between arginine and an arbitrary amino acid residue and/or a bond between lysine and an arbitrary amino acid residue, an inactivated enzyme product comprising the above-mentioned enzyme inactivated by radiation irradiation, and β-alanine. | 11-06-2008 |
20080280343 | THROMBIN PURIFICATION - The invention relates to thrombin compositions with reduced levels of high molecular weight impurities. In particular, the levels of factor Va, prions and/or viral agents are greatly reduced. This invention also relates generally to methods for the preparation of thrombin having a high degree of purity and high specific activity. More specifically, the invention encompasses steps to exclude high molecular weight impurities from thrombin preparations by size exclusion filtration. In additional embodiments, the preparation of thrombin additionally includes an ion exchange filtration step. The methods of the invention are particularly suited for large scale purification of thrombin. This invention also relates generally to stabilized formulations containing thrombin compositions. More specifically, the present invention relates to stabilized, liquid formulations containing thrombin having a high degree of purity and high specific activity and methods of making and using such formulations. | 11-13-2008 |
20080293122 | Method for Activating Prethrombin-1 - Methods for converting prethrombin-1 to thrombin are disclosed. An aqueous solution of prethrombin-1 is applied to oscutarin-C immobilized on a solid support so as to provide from 500 mg to 4000 mg of prethrombin-1 per mL of the solid support and a contact time between the prethrombin-1 and the oscutarin-C of from 1.8 to 3.5 minutes. The resulting active thrombin may be captured on an ion exchange chromatography medium or an affinity chromatography medium. | 11-27-2008 |
20090186395 | Virus Removal by Nanofiltration - A method for purifying a protein solution from infective particles comprising (a) adding a macromolecule to the solution; and (b) passing the solution through a nanofilter. The macromolecule may be selected from a polymer of at least 3 monomers of sugars, amino acids, glycols, alcohols, lipids or phospholipids. | 07-23-2009 |
20130017591 | Method for the Preparation of Recombinant Human Thrombin and Fibrinogen - The present invention discloses methods for the preparation of recombinant human proteins expressed in human cells. The present invention relates to methods for the preparation of human recombinant thrombin and human recombinant fibrinogen. The method employs serum-free culturing conditions and provides recombinant human proteins expressed in human cells of increased safety to the patient when used in human medical treatments. The immunogenic response to the recombinant human proteins expressed in human cells may be lower. Human recombinant thrombin is expressed in the human embryonic kidney 293 cell line and the protein can be prepared using two different routes, one starting from a point mutated prothrombin with gla and Kringle 1 and 2 domains, and maintaining these domains during the process; the other one starting with prothrombin (non-mutated), via a prethrombin with a HPC4-Kringle 2 domain and subjecting this prethrombin to a point mutation. | 01-17-2013 |
20130045523 | Method and Apparatus to Create Autologous Clotting Serum - A clotting serum production device including a main chamber, an inlet housing, and an outlet port. The main chamber is defined by a first end wall, a second end wall opposite to the first end wall, and a side wall extending between the first end wall and the second end wall. The inlet housing extends from the first end wall. The inlet housing includes a first inlet port, a second inlet port, and a first conduit extending between the first inlet port and a second conduit. The second conduit extends between the second inlet port and the main chamber. The inlet housing is configured to provide one-way fluid flow from the first inlet port to the second inlet port and to provide one-way fluid flow from the second inlet port to the main chamber. An outlet port is in fluid communication with the main chamber and provides fluid communication with an exterior of the clotting serum production device. | 02-21-2013 |
20130052715 | METHOD FOR PRODUCING RECOMBINANT THROMBIN - The invention relates to a method for producing folded prethrombin, wherein inclusion bodies, which contain unfolded prethrombin or a derivative thereof, are solubilized in a solubilization buffer containing at least one chaotropic compound and at least one organic disulfide compound. The invention further relates to methods for producing thrombin and a-thrombin and derivatives thereof. The invention also relates to solutions that contain folded proteins, which can be produced by the methods according to the invention. | 02-28-2013 |
20160152964 | RECOMBINANT AUTO-ACTIVATING PROTEASE PRECURSORS | 06-02-2016 |